Trial Profile

Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vemurafenib (Primary)
Indications Bladder cancer; Cholangiocarcinoma; Chronic lymphocytic leukaemia; Gastrointestinal stromal tumours; Hairy cell leukaemia; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Sarcoma; Thyroid cancer
Focus Therapeutic Use
Acronyms ACSE

Most Recent Events

06 Jun 2024 Planned End Date changed from 1 Dec 2024 to 13 Oct 2027.
06 Dec 2023 Planned End Date changed from 1 May 2024 to 1 Dec 2024.
21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com